99m Tc-MIP-1404-SPECT/CT for the detection of PSMA-positive lesions in 225 patients with biochemical recurrence of prostate cancer
Tc-MIP-1404 (Progenics Pharmaceuticals, Inc., New York, NY) is a novel, SPECT-compatible Tc-labeled PSMA inhibitor for the detection of prostate cancer. We present results of its clinical use in a cohort of 225 men with histologically confirmed prostate cancer referred for workup of biochemical rela...
Gespeichert in:
| Veröffentlicht in: | The Prostate 2018-01, Vol.78 (1), p.54-63 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 63 |
|---|---|
| container_issue | 1 |
| container_start_page | 54 |
| container_title | The Prostate |
| container_volume | 78 |
| creator | Schmidkonz, Christian Hollweg, Claudia Beck, Michael Reinfelder, Julia Goetz, Theresa I Sanders, James C Schmidt, Daniela Prante, Olaf Bäuerle, Tobias Cavallaro, Alexander Uder, Michael Wullich, Bernd Goebell, Peter Kuwert, Torsten Ritt, Philipp |
| description | Tc-MIP-1404 (Progenics Pharmaceuticals, Inc., New York, NY) is a novel, SPECT-compatible
Tc-labeled PSMA inhibitor for the detection of prostate cancer. We present results of its clinical use in a cohort of 225 men with histologically confirmed prostate cancer referred for workup of biochemical relapse.
From April 2013 to April 2017,
Tc-MIP1404-scintigraphy was performed in 225 patients for workup of PSA biochemical relapse of prostate cancer. Whole-body planar and SPECT/CT images of the lower abdomen and thorax were obtained 3-4 h p.i. of 710 ± 64 MBq
Tc-MIP-1404. Images were visually analyzed for presence and location of abnormal uptake. In addition, quantitative analysis of the SPECT/CT data was carried out on a subset of 125 patients. Follow-up reports of subsequent therapeutic interventions were available for 59% (139) of all patients.
Tracer-positive lesions were detected in 77% (174/225) of all patients. Detections occurred at the area of local recurrence in the prostate in 25% of patients (or a total of 56), with metastases in lymph nodes in 47% (105), bone in 27% (60), lung in 5% (12), and other locations in 2% (4) of patients. Detection rates were 90% at PSA levels ≥2 ng/mL and 54% below that threshold. Lesional SUVmax values were, on average, 32.2 ± 29.6 (0.8-142.2), and tumor-to-normal ratios 146.6 ± 160.5 (1.9-1482.4). The PSA level correlated significantly with total uptake of MIP-1404 in tumors (P |
| doi_str_mv | 10.1002/pros.23444 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1961036353</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1961036353</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1327-5ecb9dfa75a4f5293122776b5262e9507561431b3ec472b3eb26cd73c3baf2b3</originalsourceid><addsrcrecordid>eNo9kEtLAzEUhYMoWqsbf4BkKUJqnhOyLKVqoWKhsx8y6R0amUdNUsWtv9zU1-pyDx_nnnsQumJ0wijld7swxAkXUsojNGLUaEKpVMdoRLmmRDKhz9B5jC-UZpzyU3TGDaNKGz1Cn8Z0uHTkabEiTFJJ1qv5rLyblbgZAk5bwBtI4JIfejw0eLV-mpLdEH3yb4BbiFmP2PeYc4V3NnnoU8TvPm1x7Qe3hc472-IAbh8C9A4OJoe8ySbAzmYlXKCTxrYRLn_nGJX383L2SJbPD4vZdEkcE1wTBa42m8ZqZWWjuBGMc62LWvGCg1FUq4JJwWoBTmqeR80Lt9HCido2eR-jmx_bfP51DzFVnY8O2tb2MOxjxUzBqCiEEhm9_UFdThoDNNUu-M6Gj4rR6lB5dXih-q48w9e_vvu6g80_-tex-AJVQ3q_</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1961036353</pqid></control><display><type>article</type><title>99m Tc-MIP-1404-SPECT/CT for the detection of PSMA-positive lesions in 225 patients with biochemical recurrence of prostate cancer</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Schmidkonz, Christian ; Hollweg, Claudia ; Beck, Michael ; Reinfelder, Julia ; Goetz, Theresa I ; Sanders, James C ; Schmidt, Daniela ; Prante, Olaf ; Bäuerle, Tobias ; Cavallaro, Alexander ; Uder, Michael ; Wullich, Bernd ; Goebell, Peter ; Kuwert, Torsten ; Ritt, Philipp</creator><creatorcontrib>Schmidkonz, Christian ; Hollweg, Claudia ; Beck, Michael ; Reinfelder, Julia ; Goetz, Theresa I ; Sanders, James C ; Schmidt, Daniela ; Prante, Olaf ; Bäuerle, Tobias ; Cavallaro, Alexander ; Uder, Michael ; Wullich, Bernd ; Goebell, Peter ; Kuwert, Torsten ; Ritt, Philipp</creatorcontrib><description>Tc-MIP-1404 (Progenics Pharmaceuticals, Inc., New York, NY) is a novel, SPECT-compatible
Tc-labeled PSMA inhibitor for the detection of prostate cancer. We present results of its clinical use in a cohort of 225 men with histologically confirmed prostate cancer referred for workup of biochemical relapse.
From April 2013 to April 2017,
Tc-MIP1404-scintigraphy was performed in 225 patients for workup of PSA biochemical relapse of prostate cancer. Whole-body planar and SPECT/CT images of the lower abdomen and thorax were obtained 3-4 h p.i. of 710 ± 64 MBq
Tc-MIP-1404. Images were visually analyzed for presence and location of abnormal uptake. In addition, quantitative analysis of the SPECT/CT data was carried out on a subset of 125 patients. Follow-up reports of subsequent therapeutic interventions were available for 59% (139) of all patients.
Tracer-positive lesions were detected in 77% (174/225) of all patients. Detections occurred at the area of local recurrence in the prostate in 25% of patients (or a total of 56), with metastases in lymph nodes in 47% (105), bone in 27% (60), lung in 5% (12), and other locations in 2% (4) of patients. Detection rates were 90% at PSA levels ≥2 ng/mL and 54% below that threshold. Lesional SUVmax values were, on average, 32.2 ± 29.6 (0.8-142.2), and tumor-to-normal ratios 146.6 ± 160.5 (1.9-1482.4). The PSA level correlated significantly with total uptake of MIP-1404 in tumors (P < 0.001). Furthermore, total tumor uptake was significantly higher in patients with Gleason scores ≥8 compared to those with Gleason scores ≤7 (P < 0.05). In patients with androgen deprivation therapy, the detection rate was significantly higher compared to patients without androgen deprivation therapy (86% vs 71%, P < 0.001). Based on
Tc-MIP-1404-imaging and other information, an interdisciplinary tumor board review recommended changes to treatment plans in 74% (104/139) of those patients for whom the necessary documentation was available.
SPECT/CT with
Tc-labeled MIP-1404 has a high probability in detecting PSMA-positive lesions in patients with elevated PSA. Statistical analysis disclosed significant relationship between quantitative
Tc-MIP-1404 uptake, PSA level, and Gleason score.</description><identifier>ISSN: 0270-4137</identifier><identifier>EISSN: 1097-0045</identifier><identifier>DOI: 10.1002/pros.23444</identifier><identifier>PMID: 29105797</identifier><language>eng</language><publisher>United States</publisher><subject>Adenocarcinoma - blood ; Adenocarcinoma - diagnostic imaging ; Aged ; Aged, 80 and over ; Antigens, Surface - blood ; Glutamate Carboxypeptidase II - blood ; Humans ; Male ; Middle Aged ; Neoplasm Grading ; Neoplasm Recurrence, Local - blood ; Neoplasm Recurrence, Local - diagnostic imaging ; Prostate-Specific Antigen - blood ; Prostatic Neoplasms - blood ; Prostatic Neoplasms - diagnostic imaging ; Single Photon Emission Computed Tomography Computed Tomography ; Whole Body Imaging - methods</subject><ispartof>The Prostate, 2018-01, Vol.78 (1), p.54-63</ispartof><rights>2017 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1327-5ecb9dfa75a4f5293122776b5262e9507561431b3ec472b3eb26cd73c3baf2b3</citedby><cites>FETCH-LOGICAL-c1327-5ecb9dfa75a4f5293122776b5262e9507561431b3ec472b3eb26cd73c3baf2b3</cites><orcidid>0000-0002-1988-0058</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27907,27908</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29105797$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schmidkonz, Christian</creatorcontrib><creatorcontrib>Hollweg, Claudia</creatorcontrib><creatorcontrib>Beck, Michael</creatorcontrib><creatorcontrib>Reinfelder, Julia</creatorcontrib><creatorcontrib>Goetz, Theresa I</creatorcontrib><creatorcontrib>Sanders, James C</creatorcontrib><creatorcontrib>Schmidt, Daniela</creatorcontrib><creatorcontrib>Prante, Olaf</creatorcontrib><creatorcontrib>Bäuerle, Tobias</creatorcontrib><creatorcontrib>Cavallaro, Alexander</creatorcontrib><creatorcontrib>Uder, Michael</creatorcontrib><creatorcontrib>Wullich, Bernd</creatorcontrib><creatorcontrib>Goebell, Peter</creatorcontrib><creatorcontrib>Kuwert, Torsten</creatorcontrib><creatorcontrib>Ritt, Philipp</creatorcontrib><title>99m Tc-MIP-1404-SPECT/CT for the detection of PSMA-positive lesions in 225 patients with biochemical recurrence of prostate cancer</title><title>The Prostate</title><addtitle>Prostate</addtitle><description>Tc-MIP-1404 (Progenics Pharmaceuticals, Inc., New York, NY) is a novel, SPECT-compatible
Tc-labeled PSMA inhibitor for the detection of prostate cancer. We present results of its clinical use in a cohort of 225 men with histologically confirmed prostate cancer referred for workup of biochemical relapse.
From April 2013 to April 2017,
Tc-MIP1404-scintigraphy was performed in 225 patients for workup of PSA biochemical relapse of prostate cancer. Whole-body planar and SPECT/CT images of the lower abdomen and thorax were obtained 3-4 h p.i. of 710 ± 64 MBq
Tc-MIP-1404. Images were visually analyzed for presence and location of abnormal uptake. In addition, quantitative analysis of the SPECT/CT data was carried out on a subset of 125 patients. Follow-up reports of subsequent therapeutic interventions were available for 59% (139) of all patients.
Tracer-positive lesions were detected in 77% (174/225) of all patients. Detections occurred at the area of local recurrence in the prostate in 25% of patients (or a total of 56), with metastases in lymph nodes in 47% (105), bone in 27% (60), lung in 5% (12), and other locations in 2% (4) of patients. Detection rates were 90% at PSA levels ≥2 ng/mL and 54% below that threshold. Lesional SUVmax values were, on average, 32.2 ± 29.6 (0.8-142.2), and tumor-to-normal ratios 146.6 ± 160.5 (1.9-1482.4). The PSA level correlated significantly with total uptake of MIP-1404 in tumors (P < 0.001). Furthermore, total tumor uptake was significantly higher in patients with Gleason scores ≥8 compared to those with Gleason scores ≤7 (P < 0.05). In patients with androgen deprivation therapy, the detection rate was significantly higher compared to patients without androgen deprivation therapy (86% vs 71%, P < 0.001). Based on
Tc-MIP-1404-imaging and other information, an interdisciplinary tumor board review recommended changes to treatment plans in 74% (104/139) of those patients for whom the necessary documentation was available.
SPECT/CT with
Tc-labeled MIP-1404 has a high probability in detecting PSMA-positive lesions in patients with elevated PSA. Statistical analysis disclosed significant relationship between quantitative
Tc-MIP-1404 uptake, PSA level, and Gleason score.</description><subject>Adenocarcinoma - blood</subject><subject>Adenocarcinoma - diagnostic imaging</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antigens, Surface - blood</subject><subject>Glutamate Carboxypeptidase II - blood</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Grading</subject><subject>Neoplasm Recurrence, Local - blood</subject><subject>Neoplasm Recurrence, Local - diagnostic imaging</subject><subject>Prostate-Specific Antigen - blood</subject><subject>Prostatic Neoplasms - blood</subject><subject>Prostatic Neoplasms - diagnostic imaging</subject><subject>Single Photon Emission Computed Tomography Computed Tomography</subject><subject>Whole Body Imaging - methods</subject><issn>0270-4137</issn><issn>1097-0045</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kEtLAzEUhYMoWqsbf4BkKUJqnhOyLKVqoWKhsx8y6R0amUdNUsWtv9zU1-pyDx_nnnsQumJ0wijld7swxAkXUsojNGLUaEKpVMdoRLmmRDKhz9B5jC-UZpzyU3TGDaNKGz1Cn8Z0uHTkabEiTFJJ1qv5rLyblbgZAk5bwBtI4JIfejw0eLV-mpLdEH3yb4BbiFmP2PeYc4V3NnnoU8TvPm1x7Qe3hc472-IAbh8C9A4OJoe8ySbAzmYlXKCTxrYRLn_nGJX383L2SJbPD4vZdEkcE1wTBa42m8ZqZWWjuBGMc62LWvGCg1FUq4JJwWoBTmqeR80Lt9HCido2eR-jmx_bfP51DzFVnY8O2tb2MOxjxUzBqCiEEhm9_UFdThoDNNUu-M6Gj4rR6lB5dXih-q48w9e_vvu6g80_-tex-AJVQ3q_</recordid><startdate>201801</startdate><enddate>201801</enddate><creator>Schmidkonz, Christian</creator><creator>Hollweg, Claudia</creator><creator>Beck, Michael</creator><creator>Reinfelder, Julia</creator><creator>Goetz, Theresa I</creator><creator>Sanders, James C</creator><creator>Schmidt, Daniela</creator><creator>Prante, Olaf</creator><creator>Bäuerle, Tobias</creator><creator>Cavallaro, Alexander</creator><creator>Uder, Michael</creator><creator>Wullich, Bernd</creator><creator>Goebell, Peter</creator><creator>Kuwert, Torsten</creator><creator>Ritt, Philipp</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1988-0058</orcidid></search><sort><creationdate>201801</creationdate><title>99m Tc-MIP-1404-SPECT/CT for the detection of PSMA-positive lesions in 225 patients with biochemical recurrence of prostate cancer</title><author>Schmidkonz, Christian ; Hollweg, Claudia ; Beck, Michael ; Reinfelder, Julia ; Goetz, Theresa I ; Sanders, James C ; Schmidt, Daniela ; Prante, Olaf ; Bäuerle, Tobias ; Cavallaro, Alexander ; Uder, Michael ; Wullich, Bernd ; Goebell, Peter ; Kuwert, Torsten ; Ritt, Philipp</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1327-5ecb9dfa75a4f5293122776b5262e9507561431b3ec472b3eb26cd73c3baf2b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adenocarcinoma - blood</topic><topic>Adenocarcinoma - diagnostic imaging</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antigens, Surface - blood</topic><topic>Glutamate Carboxypeptidase II - blood</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Grading</topic><topic>Neoplasm Recurrence, Local - blood</topic><topic>Neoplasm Recurrence, Local - diagnostic imaging</topic><topic>Prostate-Specific Antigen - blood</topic><topic>Prostatic Neoplasms - blood</topic><topic>Prostatic Neoplasms - diagnostic imaging</topic><topic>Single Photon Emission Computed Tomography Computed Tomography</topic><topic>Whole Body Imaging - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schmidkonz, Christian</creatorcontrib><creatorcontrib>Hollweg, Claudia</creatorcontrib><creatorcontrib>Beck, Michael</creatorcontrib><creatorcontrib>Reinfelder, Julia</creatorcontrib><creatorcontrib>Goetz, Theresa I</creatorcontrib><creatorcontrib>Sanders, James C</creatorcontrib><creatorcontrib>Schmidt, Daniela</creatorcontrib><creatorcontrib>Prante, Olaf</creatorcontrib><creatorcontrib>Bäuerle, Tobias</creatorcontrib><creatorcontrib>Cavallaro, Alexander</creatorcontrib><creatorcontrib>Uder, Michael</creatorcontrib><creatorcontrib>Wullich, Bernd</creatorcontrib><creatorcontrib>Goebell, Peter</creatorcontrib><creatorcontrib>Kuwert, Torsten</creatorcontrib><creatorcontrib>Ritt, Philipp</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Prostate</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schmidkonz, Christian</au><au>Hollweg, Claudia</au><au>Beck, Michael</au><au>Reinfelder, Julia</au><au>Goetz, Theresa I</au><au>Sanders, James C</au><au>Schmidt, Daniela</au><au>Prante, Olaf</au><au>Bäuerle, Tobias</au><au>Cavallaro, Alexander</au><au>Uder, Michael</au><au>Wullich, Bernd</au><au>Goebell, Peter</au><au>Kuwert, Torsten</au><au>Ritt, Philipp</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>99m Tc-MIP-1404-SPECT/CT for the detection of PSMA-positive lesions in 225 patients with biochemical recurrence of prostate cancer</atitle><jtitle>The Prostate</jtitle><addtitle>Prostate</addtitle><date>2018-01</date><risdate>2018</risdate><volume>78</volume><issue>1</issue><spage>54</spage><epage>63</epage><pages>54-63</pages><issn>0270-4137</issn><eissn>1097-0045</eissn><abstract>Tc-MIP-1404 (Progenics Pharmaceuticals, Inc., New York, NY) is a novel, SPECT-compatible
Tc-labeled PSMA inhibitor for the detection of prostate cancer. We present results of its clinical use in a cohort of 225 men with histologically confirmed prostate cancer referred for workup of biochemical relapse.
From April 2013 to April 2017,
Tc-MIP1404-scintigraphy was performed in 225 patients for workup of PSA biochemical relapse of prostate cancer. Whole-body planar and SPECT/CT images of the lower abdomen and thorax were obtained 3-4 h p.i. of 710 ± 64 MBq
Tc-MIP-1404. Images were visually analyzed for presence and location of abnormal uptake. In addition, quantitative analysis of the SPECT/CT data was carried out on a subset of 125 patients. Follow-up reports of subsequent therapeutic interventions were available for 59% (139) of all patients.
Tracer-positive lesions were detected in 77% (174/225) of all patients. Detections occurred at the area of local recurrence in the prostate in 25% of patients (or a total of 56), with metastases in lymph nodes in 47% (105), bone in 27% (60), lung in 5% (12), and other locations in 2% (4) of patients. Detection rates were 90% at PSA levels ≥2 ng/mL and 54% below that threshold. Lesional SUVmax values were, on average, 32.2 ± 29.6 (0.8-142.2), and tumor-to-normal ratios 146.6 ± 160.5 (1.9-1482.4). The PSA level correlated significantly with total uptake of MIP-1404 in tumors (P < 0.001). Furthermore, total tumor uptake was significantly higher in patients with Gleason scores ≥8 compared to those with Gleason scores ≤7 (P < 0.05). In patients with androgen deprivation therapy, the detection rate was significantly higher compared to patients without androgen deprivation therapy (86% vs 71%, P < 0.001). Based on
Tc-MIP-1404-imaging and other information, an interdisciplinary tumor board review recommended changes to treatment plans in 74% (104/139) of those patients for whom the necessary documentation was available.
SPECT/CT with
Tc-labeled MIP-1404 has a high probability in detecting PSMA-positive lesions in patients with elevated PSA. Statistical analysis disclosed significant relationship between quantitative
Tc-MIP-1404 uptake, PSA level, and Gleason score.</abstract><cop>United States</cop><pmid>29105797</pmid><doi>10.1002/pros.23444</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-1988-0058</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0270-4137 |
| ispartof | The Prostate, 2018-01, Vol.78 (1), p.54-63 |
| issn | 0270-4137 1097-0045 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1961036353 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adenocarcinoma - blood Adenocarcinoma - diagnostic imaging Aged Aged, 80 and over Antigens, Surface - blood Glutamate Carboxypeptidase II - blood Humans Male Middle Aged Neoplasm Grading Neoplasm Recurrence, Local - blood Neoplasm Recurrence, Local - diagnostic imaging Prostate-Specific Antigen - blood Prostatic Neoplasms - blood Prostatic Neoplasms - diagnostic imaging Single Photon Emission Computed Tomography Computed Tomography Whole Body Imaging - methods |
| title | 99m Tc-MIP-1404-SPECT/CT for the detection of PSMA-positive lesions in 225 patients with biochemical recurrence of prostate cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T04%3A33%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=99m%20Tc-MIP-1404-SPECT/CT%20for%20the%20detection%20of%20PSMA-positive%20lesions%20in%20225%20patients%20with%20biochemical%20recurrence%20of%20prostate%20cancer&rft.jtitle=The%20Prostate&rft.au=Schmidkonz,%20Christian&rft.date=2018-01&rft.volume=78&rft.issue=1&rft.spage=54&rft.epage=63&rft.pages=54-63&rft.issn=0270-4137&rft.eissn=1097-0045&rft_id=info:doi/10.1002/pros.23444&rft_dat=%3Cproquest_cross%3E1961036353%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1961036353&rft_id=info:pmid/29105797&rfr_iscdi=true |